Cargando…
Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis
BACKGROUND: Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Sa...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234547/ https://www.ncbi.nlm.nih.gov/pubmed/37262040 http://dx.doi.org/10.1371/journal.pntd.0011319 |
_version_ | 1785052515223470080 |
---|---|
author | Alshehri, Abdullah Chhonker, Yashpal S. Bala, Veenu Edi, Constant Bjerum, Catherine M. Koudou, Benjamin G. John, Lucy N. Mitjà, Oriol Marks, Michael King, Christopher L. Murry, Daryl J. |
author_facet | Alshehri, Abdullah Chhonker, Yashpal S. Bala, Veenu Edi, Constant Bjerum, Catherine M. Koudou, Benjamin G. John, Lucy N. Mitjà, Oriol Marks, Michael King, Christopher L. Murry, Daryl J. |
author_sort | Alshehri, Abdullah |
collection | PubMed |
description | BACKGROUND: Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals. METHODOLOGY / PRINCIPAL FINDINGS: In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti–infected (n = 32) and uninfected (n = 24) adults living in Côte d’Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM’s pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/F, 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex. CONCLUSION/SIGNIFICANCE: We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF. TRIAL REGISTRATION: NCT02845713; NCT03664063 |
format | Online Article Text |
id | pubmed-10234547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-102345472023-06-02 Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis Alshehri, Abdullah Chhonker, Yashpal S. Bala, Veenu Edi, Constant Bjerum, Catherine M. Koudou, Benjamin G. John, Lucy N. Mitjà, Oriol Marks, Michael King, Christopher L. Murry, Daryl J. PLoS Negl Trop Dis Research Article BACKGROUND: Ivermectin (IVM) is a broad–spectrum anthelmintic drug used to treat diseases caused by filarial worms, such as onchocerciasis and lymphatic filariasis (LF). IVM is part of a triple–drug therapy used by the Mass Drug Administration (MDA) as a preventive strategy to eradicate LF in sub–Saharan Africa. The drug shows high variability in drug exposure in previous pharmacokinetic studies. This study aims to build a population pharmacokinetic (PopPK) model to identify and quantify the possible sources of the variability of IVM exposure after a single–oral dose in LF–infected subjects and healthy individuals. METHODOLOGY / PRINCIPAL FINDINGS: In this analysis, 724 samples were collected from treatment–naïve Wuchereria bancrofti–infected (n = 32) and uninfected (n = 24) adults living in Côte d’Ivoire who had received one dose of IVM as a part of triple–drug therapy. PopPK analysis was conducted using Phoenix NLME 8.3 software. The Monte Carlo simulation based on the final model was performed to simulate drug exposure among different dosing groups (200 μg/kg, 18 mg, and 36 mg). A two–compartment model with zero–order dose input into the absorption compartment with a lag time function followed by first–order absorption and linear elimination best described the IVM’s pharmacokinetic (PK) parameters. The final model identifies that the PK parameters of IVM are not affected by LF infection. Sex was a significant covariate on the peripheral volume of distribution (Vp/F, 53% lower in men than in women). IVM drug exposure shows linear pharmacokinetic behavior among the simulated dosing groups with similar drug exposure based on sex. CONCLUSION/SIGNIFICANCE: We have developed a PopPk model to describe and identify possible sources of the variability of IVM exposure. To our knowledge, this is the first PopPK study of IVM in patients with LF. TRIAL REGISTRATION: NCT02845713; NCT03664063 Public Library of Science 2023-06-01 /pmc/articles/PMC10234547/ /pubmed/37262040 http://dx.doi.org/10.1371/journal.pntd.0011319 Text en © 2023 Alshehri et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Alshehri, Abdullah Chhonker, Yashpal S. Bala, Veenu Edi, Constant Bjerum, Catherine M. Koudou, Benjamin G. John, Lucy N. Mitjà, Oriol Marks, Michael King, Christopher L. Murry, Daryl J. Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title_full | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title_fullStr | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title_full_unstemmed | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title_short | Population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
title_sort | population pharmacokinetic model of ivermectin in mass drug administration against lymphatic filariasis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234547/ https://www.ncbi.nlm.nih.gov/pubmed/37262040 http://dx.doi.org/10.1371/journal.pntd.0011319 |
work_keys_str_mv | AT alshehriabdullah populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT chhonkeryashpals populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT balaveenu populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT ediconstant populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT bjerumcatherinem populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT koudoubenjaming populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT johnlucyn populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT mitjaoriol populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT marksmichael populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT kingchristopherl populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis AT murrydarylj populationpharmacokineticmodelofivermectininmassdrugadministrationagainstlymphaticfilariasis |